. 2021 Jul 1;22(3):935. doi: 10.3892/etm.2021.10367

Table I.

CI values of growth inhibition by paclitaxel/cisplatin/olaparib in combination for A2780 and OVCAR-3 cell lines.

	CI
Cell line	Combination	0.0625xIC₅₀	0.125xIC₅₀	0.25xIC₅₀	0.5xIC₅₀	1xIC₅₀	2xIC₅₀	CI ED₅₀	CI ED₇₅	CI ED₉₀	CI Ave ED_50-90
A2780	Paclitaxel+Cisplatin	6.43	0.66	0.68	0.77	0.94	1.55	1.00	0.99	1.06	1.02
	Paclitaxel+Olaparib	0.77	0.27	0.52	1.07	0.76	1.51	0.59	1.38	4.02	2.00
	Cisplatin+Olaparib	0.29	0.11	0.28	0.48	0.48	0.58	0.32	1.14	0.68	0.71
OVCAR-3	Paclitaxel+Cisplatin	0.55	0.71	1.35	2.05	2.08	1.54	1.57	3.89	9.65	17.93
	Paclitaxel+Olaparib	1.16	0.92	1.21	2.75	1.94	1.72	1.82	2.80	4.31	5.77
	Cisplatin+Olaparib	0.35	0.70	0.87	1.41	1.38	0.86	0.92	1.75	3.35	5.22

The combined treatment was performed at the indicated fixed 1:1 ratio relative to their respective IC₅₀ concentrations. CI values were calculated for each constant ratio combination and at effect levels ED₅₀, ED₇₅ and ED₉₀ from the average of at least three independent experiments. CI values (<1.0) are highlighted in bold font. CI, combination index; ED, median effective dose.